KYVERNA THERAPEUTICS INC (KYTX) Fundamental Analysis & Valuation

NASDAQ:KYTX • US5019761049

Current stock price

8.87 USD
+0.1 (+1.14%)
At close:
9.04 USD
+0.17 (+1.92%)
After Hours:

This KYTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. KYTX Profitability Analysis

1.1 Basic Checks

  • In the past year KYTX has reported negative net income.
  • In the past year KYTX has reported a negative cash flow from operations.
  • In the past 5 years KYTX always reported negative net income.
  • In the past 5 years KYTX always reported negative operating cash flow.
KYTX Yearly Net Income VS EBIT VS OCF VS FCFKYTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 2025 -50M -100M -150M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -86.02%, KYTX is doing worse than 70.41% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -105.95%, KYTX is in line with its industry, outperforming 42.94% of the companies in the same industry.
Industry RankSector Rank
ROA -86.02%
ROE -105.95%
ROIC N/A
ROA(3y)-55.05%
ROA(5y)N/A
ROE(3y)-77.43%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KYTX Yearly ROA, ROE, ROICKYTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 2025 -20 -40 -60 -80 -100

1.3 Margins

  • KYTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KYTX Yearly Profit, Operating, Gross MarginsKYTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. KYTX Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, KYTX has more shares outstanding
  • The debt/assets ratio for KYTX is higher compared to a year ago.
KYTX Yearly Shares OutstandingKYTX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2025 20M 40M 60M
KYTX Yearly Total Debt VS Total AssetsKYTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • KYTX has an Altman-Z score of 3.62. This indicates that KYTX is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of KYTX (3.62) is better than 69.44% of its industry peers.
  • KYTX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • KYTX has a Debt to Equity ratio (0.00) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.62
ROIC/WACCN/A
WACCN/A
KYTX Yearly LT Debt VS Equity VS FCFKYTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • KYTX has a Current Ratio of 5.16. This indicates that KYTX is financially healthy and has no problem in meeting its short term obligations.
  • KYTX has a Current ratio of 5.16. This is comparable to the rest of the industry: KYTX outperforms 56.67% of its industry peers.
  • KYTX has a Quick Ratio of 5.16. This indicates that KYTX is financially healthy and has no problem in meeting its short term obligations.
  • KYTX has a Quick ratio (5.16) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 5.16
Quick Ratio 5.16
KYTX Yearly Current Assets VS Current LiabilitesKYTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. KYTX Growth Analysis

3.1 Past

  • The earnings per share for KYTX have decreased by -5.19% in the last year.
EPS 1Y (TTM)-5.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.09%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • KYTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.26% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y2.52%
EPS Next 2Y4.76%
EPS Next 3Y-6.68%
EPS Next 5Y10.26%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KYTX Yearly Revenue VS EstimatesKYTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
KYTX Yearly EPS VS EstimatesKYTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5

More info and screens

Find the best growth stocksShow best growing peers

0

4. KYTX Valuation Analysis

4.1 Price/Earnings Ratio

  • KYTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year KYTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KYTX Price Earnings VS Forward Price EarningsKYTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KYTX Per share dataKYTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

  • KYTX's earnings are expected to decrease with -6.68% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.76%
EPS Next 3Y-6.68%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. KYTX Dividend Analysis

5.1 Amount

  • KYTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KYTX Fundamentals: All Metrics, Ratios and Statistics

KYVERNA THERAPEUTICS INC

NASDAQ:KYTX (4/2/2026, 8:00:03 PM)

After market: 9.04 +0.17 (+1.92%)

8.87

+0.1 (+1.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-26
Earnings (Next)05-11
Inst Owners75.54%
Inst Owner Change67.86%
Ins Owners0.24%
Ins Owner Change3.3%
Market Cap506.74M
Revenue(TTM)N/A
Net Income(TTM)-160.99M
Analysts85
Price Target28.76 (224.24%)
Short Float %8.28%
Short Ratio5.99
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.54%
Min EPS beat(2)8.85%
Max EPS beat(2)14.24%
EPS beat(4)3
Avg EPS beat(4)7.36%
Min EPS beat(4)-2.95%
Max EPS beat(4)14.24%
EPS beat(8)5
Avg EPS beat(8)-88.87%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.74%
EPS NY rev (1m)0%
EPS NY rev (3m)1.16%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.34
P/tB 3.34
EV/EBITDA N/A
EPS(TTM)-3.65
EYN/A
EPS(NY)-3.56
Fwd EYN/A
FCF(TTM)-2.77
FCFYN/A
OCF(TTM)-2.75
OCFYN/A
SpS0
BVpS2.66
TBVpS2.66
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -86.02%
ROE -105.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.05%
ROA(5y)N/A
ROE(3y)-77.43%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 56.57%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.16
Quick Ratio 5.16
Altman-Z 3.62
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)70.94%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.09%
EPS Next Y2.52%
EPS Next 2Y4.76%
EPS Next 3Y-6.68%
EPS Next 5Y10.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-40.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-19.73%
EBIT Next 3Y-10.13%
EBIT Next 5YN/A
FCF growth 1Y-268.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-268.57%
OCF growth 3YN/A
OCF growth 5YN/A

KYVERNA THERAPEUTICS INC / KYTX Fundamental Analysis FAQ

What is the fundamental rating for KYTX stock?

ChartMill assigns a fundamental rating of 2 / 10 to KYTX.


What is the valuation status for KYTX stock?

ChartMill assigns a valuation rating of 0 / 10 to KYVERNA THERAPEUTICS INC (KYTX). This can be considered as Overvalued.


What is the profitability of KYTX stock?

KYVERNA THERAPEUTICS INC (KYTX) has a profitability rating of 0 / 10.


How financially healthy is KYVERNA THERAPEUTICS INC?

The financial health rating of KYVERNA THERAPEUTICS INC (KYTX) is 5 / 10.